Bifonazole spray once daily + Bifonazole spray twice daily + Placebo + Placebo + Lamisil Once
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tinea Pedis
Conditions
Tinea Pedis
Trial Timeline
Dec 1, 2009 → May 1, 2010
NCT ID
NCT01013909About Bifonazole spray once daily + Bifonazole spray twice daily + Placebo + Placebo + Lamisil Once
Bifonazole spray once daily + Bifonazole spray twice daily + Placebo + Placebo + Lamisil Once is a phase 2 stage product being developed by Bayer for Tinea Pedis. The current trial status is completed. This product is registered under clinical trial identifier NCT01013909. Target conditions include Tinea Pedis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01013909 | Phase 2 | Completed |
Competing Products
20 competing products in Tinea Pedis